DPP-4 Inhibitors Repress NLRP3 Inflammasome and Interleukin-1beta via GLP-1 Receptor in Macrophages Through Protein Kinase C Pathway

Cardiovascular Drugs and Therapy

Volumn 28, Issue 5, 2014, Pages 425-432

  Dai, Yao ^a,b   Dai, Dongsheng ^b   Wang, Xianwei ^a   Ding, Zufeng ^a   Mehta, Jawahar L ^a  

^a CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^b ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

DPP 4; GLP 1; Inflammation; PKC

Indexed keywords

6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; ANTIINFLAMMATORY AGENT; CRYOPYRIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INFLAMMASOME; INTERLEUKIN 1BETA; LIRAGLUTIDE; OXIDIZED LOW DENSITY LIPOPROTEIN; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C; SITAGLIPTIN; TOLL LIKE RECEPTOR 4; 1-(((2-((5-CYANOPYRIDIN-2-YL)AMINO)ETHYL)AMINO)ACETYL)-2-CYANO-(S)-PYRROLIDINE; 4-O-METHYL-12-O-TETRADECANOYLPHORBOL 13-ACETATE; CARRIER PROTEIN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; NITRILE; NLRP3 PROTEIN, HUMAN; PYRAZINE DERIVATIVE; PYRROLIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; INFLAMMATION; MACROPHAGE; PROTEIN EXPRESSION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CULTURE TECHNIQUE; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

CARRIER PROTEINS; CELL CULTURE TECHNIQUES; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GENE EXPRESSION REGULATION; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INFLAMMASOMES; INTERLEUKIN-1BETA; MACROPHAGES; NITRILES; PHOSPHORYLATION; PROTEIN KINASE C; PYRAZINES; PYRROLIDINES; RECEPTORS, GLUCAGON; SIGNAL TRANSDUCTION; TETRADECANOYLPHORBOL ACETATE; TOLL-LIKE RECEPTOR 4; TRIAZOLES;

EID: 84919712450     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-014-6539-4     Document Type: Article

References (37)

1. Ross R, Agius L. The process of atherogenesis–cellular and molecular interaction: from experimental animal models to humans. Diabetologia. 1992;35:S34–40.
2. Ishigaki Y, Katagiri H, Gao J, et al. Impact of plasma oxidized low-density lipoprotein removal on atherosclerosis. Circulation. 2008;118:75–83.
3. Masters SL, Dunne A, Subramanian SL, et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat Immunol. 2010;11:897–904.
4. Pant S, Deshmukh A, Mehta JL. Inflammation and atherosclerosis—revisited. J Cardiovasc Pharmacol Ther. 2014;19:168–76.
5. Satoh T, Kambe N, Matsue H. NLRP3 activation induces ASC-dependent programmed necrotic cell death, which leads to neutrophilic inflammation. Cell Death Dis. 2013;4:e644.
6. Jiang Y, Wang M, Huang K, et al. Oxidized low-density lipoprotein induces secretion of interleukin-1β by macrophages via reactive oxygen species-dependent NLRP3 inflammasome activation. Biochem Biophys Res Commun. 2012;425:121–6.
7. Liu W, Yin Y, Zhou Z, He M, Dai Y. OxLDL-induced IL-1beta secretion promoting foam cells formation was mainly via CD36 mediated ROS production leading to NLRP3 inflammasome activation. Inflamm Res. 2014;63:33–43.
8. Shiloh Y, Ziv Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat Rev Mol Cell Biol. 2013;14:197–210.
9. Ma L, Dong F, Denis M, et al. Ht31, a protein kinase a anchoring inhibitor, induces robust cholesterol efflux and reverses macrophage foam cell formation through ATP-binding cassette transporter A1. J Biol Chem. 2011;286:3370–8.
10. Kong L, Shen X, Lin L, et al. PKCβ promotes vascular inflammation and acceleration of atherosclerosis in diabetic ApoE Null Mice. Arterioscler Thromb Vasc Biol. 2013;33:1779–87.
11. Ma L, Dong F, Zaid M, Kumar A, Zha X. ABCA1 protein enhances toll-like receptor 4 (TLR4)-stimulated interleukin-10 (IL-10) secretion through protein kinase a (PKA) activation. J Biol Chem. 2012;287:40502–12.
12. Namba M, Katsuno T, Kusunoki Y, et al. New strategy for the treatment of type 2 diabetes mellitus with incretin-based therapy. Clin Exp Nephrol. 2013;17:10–5.
13. Ervinna N, Mita T, Yasunari E, et al. Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice. Endocrinology. 2013;154:1260–70.
14. Shah Z, Kampfrath T, Deiuliis JA, et al. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation. 2011;124:2338–49.
15. Matsubara J, Sugiyama S, Akiyama E, et al. Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes. Circ J. 2013;77:1337–44.
16. Krijnen PA, Hahn NE, Kholová I, et al. Loss of DPP4 activity is related to a prothrombogenic status of endothelial cells: implications for the coronary microvasculature of myocardial infarction patients. Basic Res Cardiol. 2012;107:233.
17. Park EK, Jung HS, Yang HI, et al. Optimized THP-1 differentiation is required for the detection of responses to weak stimuli. Inflamm Res. 2007;56:45–50.
18. Voloshyna I, Modayil S, Littlefield MJ, et al. Plasma from rheumatoid arthritis patients promotes pro-atherogenic cholesterol transport gene expression in THP-1 human macrophages. Exp Biol Med (Maywood). 2013;238:1192–7.
19. Chua S, Sheu JJ, Chen YL, et al. Sitagliptin therapy enhances the number of circulating angiogenic cells and angiogenesis-evaluations in vitro and in the rat critical limb ischemia model. Cytotherapy. 2013;15:1148–63.
20. Dai Y, Mercanti F, Dai D, et al. LOX-1, a bridge between GLP-1R and mitochondrial ROS generation in human vascular smooth muscle cells. Biochem Biophys Res Commun. 2013;437:62–6.
21. Huang W, Ishii I, Zhang WY, Sonobe M, Kruth HS. PMA activation of macrophages alters macrophage metabolism of aggregated LDL. J Lipid Res. 2002;43:1275–82.
22. Dai Y, Su W, Ding Z, et al. Regulation of MSR-1 and CD36 in macrophages by LOX-1 mediated through PPAR-γ. Biochem Biophys Res Commun. 2013;431:496–500.
23. Dai Y, Mehta JL, Chen M. Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation. Cardiovasc Drugs Ther. 2013;27:371–80.
24. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol. 2001;1:135–45.
25. Terasaki M, Nagashima M, Nohtomi K, et al. Preventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to Incretin’s actions in nondiabetic and diabetic apolipoprotein E-null mice. PLoS One. 2013;8:e70933.
26. Jose T, Inzucchi SE. Cardiovascular effects of the DPP-4 inhibitors. Diab Vasc Dis. 2012;9:109–16.
27. Hayden JM, Reaven PD. Cardiovascular disease in diabetes mellitus type 2: a potential role for novel cardiovascular risk factors. Curr Opin Lipidol. 2000;11:519–28.
28. Ding Z, Liu S, Wang X, Khaidakov M, Dai Y, Mehta JL. Oxidant stress in mitochondrial DNA damage, autophagy and inflammation in atherosclerosis. Sci Rep. 2013;3:1077.
29. Lu X, Kakkar V. Inflammasome and atherogenesis. Curr Pharm Des. 2013 [Epub ahead of print]
30. Manica-Cattani MF, Duarte MM, Ribeiro EE, de Oliveira R. Mânica da Cruz IB. Effect of the interleukin-1B gene on serum oxidized low-density lipoprotein levels. Clin Biochem. 2012;45:641–5.
31. Lundberg AM, Ketelhuth DF, Johansson ME, et al. Toll-like receptor 3 and 4 signalling through the TRIF and TRAM adaptors in haematopoietic cells promotes atherosclerosis. Cardiovasc Res. 2013;99:364–73.
32. Blich M, Golan A, Arvatz G, et al. Macrophage activation by heparanase is mediated by TLR-2 and TLR-4 and associates with plaque progression. Arterioscler Thromb Vasc Biol. 2013;33:e56–65.
33. Liu R, He Y, Li B, et al. Tenascin-C produced by oxidized LDL-stimulated macrophages increases foam cell formation through Toll-like receptor-4. Mol Cells. 2012;34:35–41.
34. Xu XH, Shah PK, Faure E, et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation. 2001;104:3103–8.
35. Kaur H, Chien A, Jialal I. Hyperglycemia induces toll like receptor 4 expression and activity in mouse mesangial cells: relevance to diabetic nephropathy. Am J Physiol Renal Physiol. 2012;303:F1145–50.
36. Wardill HR, Gibson RJ, Logan RM, Bowen JM. TLR4/PKC-mediated tight junction modulation: a clinical marker of chemotherapy-induced gut toxicity? Int J Cancer. 2013 Dec 6. doi: 10.1002/ijc.28656. [Epub ahead of print]
37. Qu Y, Misaghi S, Izrael-Tomasevic A, et al. Phosphorylation of NLRC4 is critical for inflammasome activation. Nature. 2012;490:539–42.